HCA Healthcare planned sale of 8,020 common shares

A shareholder of HCA Healthcare, Inc. filed a Rule 144 notice to sell 8,020 shares of common stock, with an aggregate market value of 4,126,949.9.

Rhea-AI Filing Summary

A shareholder of HCA Healthcare, Inc. filed a Rule 144 notice to sell 8,020 shares of common stock, with an aggregate market value of 4,126,949.9. The planned sale is through Merrill Lynch on the NYSE, with an approximate sale date of 02/11/2026.

The shares to be sold were acquired via vesting of stock awards from HCA Healthcare, Inc. on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment. The notice also states that the seller represents they do not know any undisclosed material adverse information about HCA’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for HCA indicate?

The Form 144 indicates a shareholder plans to sell 8,020 HCA Healthcare common shares under Rule 144. The planned transaction has an aggregate market value of 4,126,949.9 and is scheduled for execution on or around 02/11/2026 through Merrill Lynch on the NYSE.

How were the HCA shares in this Form 144 acquired?

The shares were acquired through vesting of stock awards from HCA Healthcare, Inc. Awards vested on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment for the holder.

What is the planned sale method for the HCA shares in this Rule 144 notice?

The notice states the 8,020 common shares are to be sold through Merrill Lynch at its Atlanta, Georgia office. The intended marketplace is the NYSE, with an approximate sale date of 02/11/2026, subject to market conditions and applicable rules.

How many HCA shares are outstanding in this Form 144 disclosure?

The filing reports 228,193,900 HCA common shares outstanding in the class referenced. This figure provides context for the planned sale of 8,020 shares under Rule 144, showing the transaction’s relative size versus the total outstanding shares.

What representation does the seller make in the HCA Form 144?

The seller represents that they do not know any material adverse information about HCA Healthcare’s current or prospective operations that has not been publicly disclosed. This representation is explicitly stated as part of signing the notice required for the planned Rule 144 sale.

Does the HCA Form 144 mention Rule 10b5-1 trading plans?

Yes. The notice explains that if the person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1, by signing they make the same representation as of the plan’s adoption or instruction date, regarding undisclosed material adverse information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:37 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001793262
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	HCA Healthcare, Inc.
SEC File Number	001-11239
Address of Issuer	One Park Plaza Nashville TENNESSEE 37203
Phone	6153449551
Name of Person for Whose Account the Securities are To Be Sold	Jennifer L. Berres
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3455 Peachtree Road NE STE 1000 Atlanta GA 30326	8020	4126949.9	228193900	02/11/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2023	Vesting of a Stock Award	HCA Healthcare, Inc.			5159	02/17/2023	Compensatory Payment
Common	02/16/2024	Vesting of a Stock Award	HCA Healthcare, Inc.			1680	02/16/2024	Compensatory Payment
Common	02/13/2025	Vesting of a Stock Award	HCA Healthcare, Inc.			1181	02/13/2025	Compensatory Payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jennifer Berres
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)